Dimethyl fumarate - Almirall

Drug Profile

Dimethyl fumarate - Almirall

Alternative Names: LAS-41008; Skilarence

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Almirall S.A.
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Marketed Plaque psoriasis

Most Recent Events

  • 27 Jul 2017 Launched for Plaque psoriasis in United Kingdom (PO) before July 2017 - First Global Launch
  • 23 Jun 2017 Registered for Plaque psoriasis in Liechtenstein, Norway, Iceland, European Union (PO) - First Global Approval (EMA website; 3271919)
  • 21 Apr 2017 Committee for Medicinal Products for Human Use (CHMP) of the EMA recommends approval of Dimethyl fumarate for Plaque psoriasis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top